Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 73 | ECE2021 | Next issue

European Congress of Endocrinology 2021

Online
22 May 2021 - 26 May 2021

Card image cap
The European Congress of Endocrinology provides a global platform for the international endocrine community to discuss the latest advances in the field.

Oral Communications

Oral Communications 13: Pituitary and Neuroendocrinology

ea0073oc13.1 | Oral Communications 13: Pituitary and Neuroendocrinology | ECE2021

TP53 mutations in functional corticotroph tumours: prevalence and clinical relevance

Perez-Rivas Luis Gustavo , Simon Julia , Albani Adriana , Rotermund Roman , Hermus Perez-Rivas , Guillaume Assié , Gadelha Monica , Deutschbein Timo , Flitsch Jörg , Honegger Jürgen , Rachinger Walter , Stalla Günter , Reincke Martin , Theodoropoulou Marily

IntroductionTP53 mutations have been rarely reported in pituitary tumours. Recently two exploratory exome sequencing studies have identified somatic TP53 mutations in a small number of functional corticotroph tumours (6/18 and 4/10) with USP8 wild type (wt) status, suggesting that they may be more frequent than previously thought. Nevertheless, the clinical impact of those mutations is still unknown.AimTo det...

ea0073oc13.2 | Oral Communications 13: Pituitary and Neuroendocrinology | ECE2021

In vitro activity of glutamate decarboxylase types, 65 and 67 in GABAergic brain-regions sleeping-process related

Cabeza Marisa , Carrasco-Núñez Nayely , Romano Martha

We determined in vitro activity of 17β-estradiol and or progesterone on glutamate conversion to GABA in different GABAergic regions from the brain of castrated and non-castrated rats. The glutamate decarboxylase catalyzes this conversion; there are two different isotypes of glutamate decarboxylase, GAD65 and GAD67. Whereas GAD65 is a membrane enzyme, GAD67 is present in the supernatant obtained after centrifuging to 14,...

ea0073oc13.3 | Oral Communications 13: Pituitary and Neuroendocrinology | ECE2021

Cardiovascular and metabolic safety of growth hormone treatment in adult patients with growth hormone deficiency: real-world data from two large studies in the USA and Europe

Charlotte Höybye , Kelepouris Nicky , Nedjatian Navid

IntroductionEvidence suggests that adults with growth hormone deficiency (AGHD) exhibit metabolic abnormalities that are typical of the metabolic syndrome and are risk factors for type 2 diabetes (T2D). Concerns about undesirable effects of growth hormone replacement therapy (GHRT) on glucose metabolism have been raised, but the risk of T2D from AGHD has mixed evidence. This analysis aims to evaluate cardiovascular (CV) and metabolic safety of GHRT in th...

ea0073oc13.4 | Oral Communications 13: Pituitary and Neuroendocrinology | ECE2021

Growth hormone-releasing hormone (GHRH) promotes survival and proliferation of neural stem cells and reduces amyloid-β-induced toxicity

Banfi Dana , Gesmundo Iacopo , Guglielmotto Michela , Tamagno Elena , Ghigo Ezio , Schally Andrew V. , Granata Riccarda

Neurogenesis, a process by which new neurons are generated from precursors, still persists in discrete regions of the adult hippocampus. The hippocampus is critical for learning and memory and is a main target of AD, which causes massive neuronal death, reduction in neurogenesis and impairment in cognitive functions. Therefore, preventing neuronal loss or increasing the production of new neurons may represent a potential therapeutic strategy to reduce AD-induced cognitive decl...

ea0073oc13.5 | Oral Communications 13: Pituitary and Neuroendocrinology | ECE2021

Potential therapeutic role of somatostatin and cortistatin in prostate cancer

Gomez Jesus Perez , Sáez-Mart Prudencio , Jiménez-Vacas Juan M. , Herrero-Aguayo nez-Vacas> , Pedraza-Arévalo Sergio , Enrique Gómez-Gómez , León-González Antonio J. , Martínez-Fuentes Antonio J. , Castaño Antonio J. , Gahete Manuel D. , Luque Raúl M.

Somatostatin (SST), Cortistatin (CORT), Neuronostatin (NST) and their receptors [SST/CORT-receptors (sst1–5/sst5TMD4-TMD5) and NST-receptor (GPR107)] comprise a hormonal pleiotropic system involved in the regulation of multiple pathophysiological functions. Certain components of this system are dysregulated in endocrine-related cancers, including prostate cancer (PCa), wherein we have found that alterations in specific components of this regulatory system [i.e. NST-GPR10...

ea0073oc13.6 | Oral Communications 13: Pituitary and Neuroendocrinology | ECE2021

A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands

Fleseriu Maria , Dreval Alexander V. , Pokramovich Yulia , Bondar Irina , Isaeva Elena , Molitch Mark E. , Macut Djuro P. , Leonova Nina , Raverot Gerald , Grineva Elena , Poteshkin Yury E. , Gilgun-Sherki Yossi G , Ludlam William H. , Patou Gary , Haviv Asi , Gordon Murray B. , Biermasz Nienke , Melmed Shlomo K. , Strasburger Yossi G

BackgroundMPOWERED, a large phase 3 trial, assessed maintenance of response to oral octreotide capsules (OOC; MYCAPSSA) compared to injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly who responded to OOC and iSRLs (octreotide or lanreotide). OOC were recently approved in the US for patients with acromegaly who responded to and tolerated iSRLs.MethodsEligibility criteria included age ...